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Abstract
Bacground: To assess the contribution of macroprolactin to high serum prolactin levels and their association with
thyroid status and thyroid autoimmunity during pregnancy.
Methods: 138 pregnant women who suspected of having thyroid dysfunction were studied and divided into three
groups according to the thyroid status; group 1; euthyroidism (n 40), group 2; hypothyroidism (n 54), and group 3;
hyperthyroid (n 44). Polyethylene glycol (PEG) precipitation method was used for detection of macroprolactin. A
percentage recovery of 40 % or less is considered as macroprolactinemia. If macroprolactin was negative, the
percentage of monomeric prolactin recovery (monoPRL %) after PEG precipitation was used for comparison
between the groups.
Results: Macroprolactinemia was found in two patients (1.4 %) one from hypothyroid and other from euthyroid
group. Basal prolactin levels in these patients were 400 and 403 ng/mL respectively. Referring to all patients, there
was no correlation between PRL, macroPRL or monoPRL % with thyroid hormone status and also with the serum
levels of thyroid antibodies (p > 0.05). A positive correlation was observed between the serum levels of PRL with
TSH (p = 0.014 and r = 0.219), while a negative correlation was found with FT4 (p = 0.011 and r = −0.227).
Conclusions: Despite the fact that serum prolactin levels were found to be high during pregnancy, the contribution of
macroprolactin was found to be insignificant in our study. Unlike other auto immune diseases, we could not find any
relationship between thyroid autoimmunity and PRL, macroPRL or monoPRL %. These results confirmed that measured
prolactin was quite homogeneous during pregnancy.
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Background
Prolactin, a protein hormone, is secreted from the anter-
ior pituitary usually in response to physiological and
rarely pathological stimuli. Prolactin concentrations
begin to increase after 6 weeks of pregnancy and reach
the highest level in late pregnancy to prepare the mam-
mary glands of the breasts for the production of milk
[1–3]. It is well known that circulating prolactin is not
homogenous and three different forms are defined ac-
cording to molecular size: monomeric PRL (monoPRL),
big PRL (bigPRL), and macroprolactin (macroPRL).
Macroprolactin is described as a complex of PRL with
immunoglobulin G (IgG) which is related to antiprolac-
tin autoantibodies. This formulation of PRL may cause
limited bioactivity, bioavailability and clearance from the
glomerulus. Macroprolactinemia is usually asymptom-
atic, patients with macroprolactinemia do not need fur-
ther therapy, and pregnancy is possible without any
treatment for such hyperprolactinemia [4–6]. Although
the gold standard method for detecting macroPRL is gel
filtration chromatography, precipitation with polyethyl-
ene glycol (PEG) is a widely used screening test. A low
PRL recovery, <40 %, after PEG precipitation indicates
the presence of macroPRL [7, 8]. In hyperprolactinemic
states, the contribution of macroprolactin has been
found to be 10 to 25 % of prolactin and macroprolacti-
nemia may be present in about 0.2–3.6 % of the general
population [9].
Normal maternal thyroid function is essential for
both fetal and maternal health and many physiological
alterations occur during pregnancy. Human chorionic
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gonadotropin (hCG) and estrogen are two pregnancy-
related hormones responsible for increased thyroid
hormone levels in the blood. Thyroid disorders, particularly
those with autoimmune origin, are common in women of
reproductive age and both hypo and hyperthyroidism were
reported to be associated with poor pregnancy outcome
[10–12]. Therefore, different trimester-specific reference
ranges were defined to distinguish physiological alterations
from pathological states [13–15]. It has been shown that
the thyrotropin-releasing hormone (TRH) can stimulate
the secretion of prolactin in experimental conditions; how-
ever its physiological influence is not so obvious.
Hypothyroidism may cause pituitary and thyrotrophic
hyperplasia which result in elevated TRH and prolactin
release. The high levels of both hormones may return
to normal after effective thyroid hormone replacement
therapy [16, 17].
Previous studies have shown that prolactin also plays
an essential role in metabolism and regulation of the im-
mune system and macroprolactin has been described as
the major immune reactive prolactin species in the
serum of several subjects before and during pregnancy.
The relationship with anti-PRL autoantibodies and auto-
immune disorders has been investigated in some studies
due to the structure of macroprolactin [18, 19]. Al-
though some case reports have shown interaction be-
tween macroprolactinemia and autoimmune thyroid
disorders, other studies examining a large number of pa-
tients revealed no specific association. It has been shown
that only a minority of patients with SLE had higher fre-
quencies of macroprolactinemia [20, 21]. The association
of prolactin and macroprolactin with thyroid hormones
and thyroid autoantibodies during pregnancy has not
been studied before.
In the present study, we aimed to assess the contribu-
tion of macroprolactin to high serum prolactin levels
and the association of prolactin (PRL) and macroprolac-
tin (macroPRL) levels with thyroid status and thyroid
autoimmunity during pregnancy.
Methods
The study, designed as a prospective case series, was
conducted between March 2014 and December 2014 in
the Sevket Yılmaz Research and Education Hospital,
Bursa, Turkey. Data were collected by selecting pregnant
women who had undergone a TSH screening and been
directed to endocrinology consultation. The study proto-
col was approved by the local ethics committee. A total
of 138 pregnant women suspected of having thyroid dys-
function, and who gave informed consent, were studied
in different stages of gestation. All subjects were inter-
viewed regarding reproductive history including miscar-
riages, preterm deliveries, and neonatal complications.
Personal histories of thyroid disorders and thyroid
medications were noted. Selected patients were divided
into three groups according to the ATA guidelines;
Group 1 euthyroid (TSH between 0.1 μIU/L and 2.5
μIU/L), group 2 hypothyroid (TSH ≥ 2.51 μIU/L), and
group 3 hyperthyroid (TSH ≤ 0.09 μIU/L). The TPOAb ≥
35 U/mL was considered to be antibody positive also ac-
cording to ATA guidelines [15]. History of the following
complications during previous pregnancies were consid-
ered to be complicated pregnancy; miscarriage, stillbirth,
preterm birth, fetal death, postpartum hemorrhage, pla-
cental abruption, cardiac dysfunction and maternal heart
failure, gestational hypertension, preeclampsia, gesta-
tional diabetes, and cesarean sections.
Laboratory investigation
Following an overnight fast, blood samples were acquired
in the morning from each subject. Serum was isolated by
centrifugation and stored at −80 °C until testing, if needed.
The concentrations of serum TSH, FT3 and FT4 were de-
tected by electrochemiluminescence immunoassay diagnos-
tic kit (Advia Centaur XP Siemens, USA). TGAb and
TPOAb levels were detected using an electrochemilumines-
cence immunoassay diagnostic kit (Roche Diagnostics Ltd.,
Basel, Switzerland). The concentration of serum prolactin
was detected by electrochemiluminescence immunoassay
diagnostic kit (Immulite 2000, Diagnostic Products Corpor-
ation, LA, CA). After centrifugation, the supernatant con-
taining the unprecipitated prolactin is tested for total
prolactin level. A concentration of 25 % PEG is added to an
aliquot of serum specimen and the PEG-treated sample is
incubated for a short period and then centrifuged to pre-
cipitate out macroprolactin. The supernatant containing
the unprecipitated prolactin is tested for recovery of basal
prolactin. The PEG-precipitable PRL (%), which represents
the amount of macroprolactin, is calculated as follows:
(total PRL-free PRL)/total PRL × 100. PEG-precipitation ra-
tio greater than 60 % (recovery less than 40 %) is used as
the cut-off value for the diagnosis of macroprolactinemia.
Recovery of less than 40 % after PEG is considered a diag-
nostic criteria for macroprolactin; recovery values around
40–60 % are considered borderline, and values >60 % rule
out macroprolactinemia [22–24]. The unprecipitated per-
centage of basal prolactin is considered as recovery of
monomeric prolactin.
Statistical analysis
Statistical analysis was performed using IBM-SPSS
software (version 21.0; SPSS Inc., Chicago, IL, USA).
Comparisons between groups were performed using
ANOVA for normally distributed variables, and the
Mann–Whitney and Kruskal-Wallis tests for non-
normal variables. All data are expressed as mean ±
standard deviation or percentages, while p value <0.05
was considered statistically significant.
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Results
Comparison of patients’ demographics and laboratory
parameters between the groups are shown in Table 1.
The number of patients in the euthyroid (n = 40),
hypothyroid (n = 54) and hyperthyroid (n = 44) groups
and age distributions between the groups (mean age was
29.2 ± 5.6 years in group 1, 29.0 ± 5.1 years in group 2
and 29.3 ± 4.9 years in group 3) were similar (p > 0.05).
Although it did not reach statistical significance, the
mean number of previous pregnancies was higher in
hyperthyroid patients (2.7) than hypothyroid (2.4) and
euthyroid (2.2) patients. Rates of complicated pregnancy
history were high in all groups (n = 12 (30 %) in group 1,
n = 18 (33 %) in group 2 and 14 (34 %) in group 3).
Body weight of the patients in group 3 was lower than
patients in the other groups (p < 0.005) and the mean
weight was 69.9 ± 13.9 kg in group 1, 68.7 ± 14.5 kg in
group 2 and 60.7 ± 11.5 kg in group 3. Blood pressure
measurements were not different between the groups.
Mean TSH level was 1.04 ± 0.7 μIU/L in group 1, 6.7 ±
10.7 μIU/L in group 2, and 0.02 ± 0.02 μIU/L in group 3.
Mean FT4 was 1.13 ± 0.21 ng/dL in group 1, 1.17 ±
0.54 ng/dL in group 2, and 1.7 ± 0.80 ng/dL in group 3.
Mean FT3 pg/mL was 2.93 ± 0.331 pg/mL in group 1,
2.78 ± 0.531 pg/mL in group 2, and 4.84 ± 2.04 pg/mL in
group 3. As expected, there were significant differences
in serum TSH, FT4, and FT3 levels between the groups
(p < 0.001). There were significant differences also in terms
of thyroid antibodies between the groups (p < 0.001).
TPOAb was 189.9 ± 352.6 U/mL in group 1, 563.8 ± 576.5
U/mL in group 2, and 158.8 ± 308.8 U/mL in group 3.
TGAb was 71.1 ± 111.51 U/mL in group 1, 164.7 ± 159.0
U/mL in group 2, and 123.7 ± 311.2 U/mL in group 3.
Group 2 had significantly higher TPOAb and TGAb levels
compared to group 1 and 3 (p < 0.01 and <0.05 respect-
ively). Macroprolactinemia was detected in two patients.
One patient was from group 1 and the other patient was
from group 2. Basal PRL levels of these patients were 400
and 403 ng/mL respectively. Basal serum PRL levels and
percentage of monoPRL recovery after PEG precipitation
were similar when the three groups were compared. Per-
centages of monoPRL recovery after PEG treatment were
not different between the groups; 90.6 ± 8.7 % in group 1,
91.5 ± 9.2 % in group 2, and 88.9 ± 10.9 % in group 3.
Correlation analyses of prolactin and monoPRL % with
patients’ characteristics and laboratory parameters are
summarized in Table 2.
There was a positive correlation (p < 0.001, r =0.532) be-
tween PRL with gestational week and a negative correlation
(p < 0.05, r = −0.296) with number of pregnancies. Serum
prolactin levels were also found positively correlated with
serum TSH (p = 0.014 and r = 0.219) and negatively corre-
lated with FT4 (p = 0.011 and r = −0.227). Because of the
insufficient number of macroprolactin positive patients,
correlation analyses were done between the percentages of
monoPRL recovery instead of macroprolactinemia. How-
ever, no statistically significant correlation was found be-
tween monoPRL % and thyroid hormone levels. Also, there
Table 1 Comparison of demographic and laboratory parameters between the groups
Data Group 1 Group 2 Group 3 p
Euthyroid Hypothyroid Hyperthyroid
(n = 40) (n = 54) (n = 44)
Age (years) 29.2 ± 5.6 29.0 ± 5.1 29.3 ± 4.9 NS
Mean number of pregnancies 2.2 2.4 2.7 NS
Number of patients with history of
complicated pregnancy (n)
12 18 14 NS
Weight (kg) 69.9 ± 13.9 68.7 ± 14.5 60.7 ± 11.5a,b <0.005
SBP (mmHg) 111.5 ± 12.5 111.7 ± 11.9 130.5 ± 13.7 NS
DBP (mmHg) 73.2 ± 8.9 72.3 ± 9.1 71.4 ± 10.7 NS
TSH(μIU/L) 1.04 ± 0.7 6.7 ± 10.7a,c 0.02 ± 0.02 <0.001
FT4(ng/dL) 1.13 ± 0.21 1.17 ± 0.54 1.7 ± 0.80a,b <0.001
FT3 (pg/mL) 2.93 ± 0.33 2.78 ± 0.53 4.84 ± 2.04a,b <0.001
TPOAb (U/mL) 189.9 ± 352.6 563.8 ± 576.5c 158.8 ± 308.8 <0.001
TGAb(U/mL) 71.1 ± 111.5 164.7 ± 159.0c 123.7 ± 311.2 <0.05
PRL(ng/mL) 57.4 ± 49.4 69.6 ± 74.8 54.7 ± 68.7 NS
macroPRL (n) 1 1 - NA
monoPRL % 90.6 ± 8.7 91.5 ± 9.2 88.9 ± 10.9 NS
SBP systolic blood pressure, DBP diastolic blood pressure, TSH thyroid stimulating hormone. FT4 free tetraiodotronin, FT3 free triiodotronin, TPOAb thyroid peroxidase
antibody, TGAb thyroglobulin antibody, PRL prolactin. monoPRL% the percentage of monomeric prolactin recovery after PEG precipitation
a = group 3 vs group2 p < 0.05; b = group 3 vs group 1 p < 0.001. c = group 2 vs group 1 p < 0.00
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was no correlation between the serum levels of thyroid
antibodies with PRL and monoPRL % (p > 0.05). There was
a slightly significant negative correlation between PRL and
monoPRL % (p = 0.043 and r = −0.181).
The comparisons of data obtained from patients who
were divided into two groups according to the presence
of TPOAb antibody are also seen in Table 3.
Patients with positive TPOAb had higher serum TSH
levels (3.97 ± 9.3 vs. 1.35 ± 0.62 μIU/L) and lower serum
FT4 levels (1.28 ± 0.65 vs. 1.46 + 0.62 ng/dL) compared
to patients with negative TPOAb and the differences be-
tween the groups were significant for both parameters
(p = 0.003 and 0.018 respectively). But serum FT3 levels
of the groups were similar. In addition, neither prolactin
nor monoPRL % levels were different between the pa-
tients with positive and negative TPOAb (p > 0.05).
Comparisons of PRL, monoPRL %, and thyroid param-
eters between patients with and without a history of
complicated pregnancy are shown in Table 4.
In terms of history of complicated pregnancy, there was a
slightly significant difference for PRL levels between the
groups. Patients without a history of complicated preg-
nancy had higher prolactin levels than the patients with a
history of complicated pregnancy (66.64 ± 65.9 vs. 49.12 ±
66.0 ng/ml; p = 0.026). There were also significant differ-
ences in terms of thyroid autoantibodies between the two
groups. Patients with a history of complicated pregnancy
had higher antibody levels. Serum TPOAb and TGAb levels
were 344.7 ± 496.9 U/mL and 169.3 ± 329.2 U/mL in pa-
tients with complicated pregnancy, whereas they were
207.7 ± 468.8 U/mL and 89.9 ± 134.7 U/mL in patients
without complicated pregnancy.
Discussion
Pregnancy and breastfeeding are the most important pe-
riods of long-term physiological increase of prolactin
levels. Absence of galactorrhea is mostly related with the
high levels of estrogen during pregnancy despite hyper-
prolactinemia [25]. On the other hand, a probable alter-
native explanation for the absence of galactorrhea may
be heterogeneity of prolactin molecules. It is well
known that high-molecular weight isoforms of PRL
have low binding affinity to PRL receptors. In addition,
it was shown that the relative proportion of little PRL
increased in pregnant women as pregnancy progressed [1].
In some studies, the presence of big, big PRL has been
reported in a range of 8–38 % of total PRL during preg-
nancy [26, 27]. However, Hattori et al. [28] has found that
the frequency of macroprolactinemia was 2.9 % in women
during the third trimester of pregnancy (3 of 105). We
found the frequency of macroprolactinemia as 1.4 % in
women in the first and second trimester. Unlike the other
Table 2 Correlation analyses of prolactin and monoPRL % with
patient’s demographics and laboratory parameters
Data Prolactin monoPRL %
p value r p value r
Age (years) 0.635 −0.043 0.282 −0.096
Gestation week <0.001 0.532 0.114 −0.144
Number of pregnancies 0.001 −0.296 0.699 0.035
History of complicated pregnancy 0.176 −0.123 0.918 0.009
Weight 0.271 0.099 0.457 −0.067
TSH 0.014 0.219 0.341 0.086
FT4 0.011 −0.227 0.982 −0.002
FT3 0.051 −0.174 0.706 −0.034
TPOAb 0.581 −0050 0.980 −0.002
TGAb 0.766 −0.031 0.393 0.089
PRL - - 0.043 −0.181
monoPRL % 0.043 −0.181 - -
TSH thyroid stimulating hormone, FT4 free tetraiodotronin, FT3 free triiodotronin,
TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody, PRL prolactin,
monoPRL% percentage of monomeric prolactin recovery after PEG precipitation
Table 3 Comparisons of PRL and monoPRL% between patient




(n 81) (n 57)
PRL(ng/mL) 66.28 ± 73.8 53.2 ± 51.3 0.923
monoPRL % 90.73 ± 9.53 90.14 ± 10.0 0.666
TSH(μIU/L) 3.97 ± 9.3 1.35 ± 0.62 0.003
FT4(ng/dL) 1.28 ± 0.65 1.46 + 0.62 0.018
FT3 (pg/mL) 3.36 + 1.61 3.68 + 1.39 0.079
TSH thyroid stimulating hormone, FT4 free tetraiodotronin, FT3 free triiodotronin,
TPOAb thyroid peroxidase antibody, PRL prolactin, monoPRL% percentage of
monomeric prolactin recovery after PEG precipitation
Table 4 Comparisons of PRL, monoPRL %, and thyroid
parameters between patient with and without history of
complicated pregnancy
Parameter History of complicated pregnancy p
Positive Negative
(n 44) (n 94)
PRL (ng/mL) 49.12 ± 66.0 66.64 ± 65.9 0.026
monoPRL % 90.7 ± 11.1 90.50 ± 9.02 0.788
TSH(μIU/L) 2.72 ± 4.01 3.06 ± 8.5 0.655
FT4(ng/dL) 1.28 ± 0.49 1.37 + 1.67 0.305
FT3 (pg/mL) 3.32 + 1.14 3.59 + 1.67 0.811
TPOAb (U/mL) 344.7 ± 496.9 207.7 ± 468.8 0.045
TGAb(U/mL) 169.3 ± 329.2 89.9 ± 134.7 0.026
TSH thyroid stimulating hormone, FT4 free tetraiodotronin, FT3 free triiodotronin,
TPOAb thyroid peroxidase antibody, PRL prolactin, monoPRL% percentage of
monomeric prolactin recovery after PEG precipitation
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studies [26, 27], our results were similar to the results of
Hattori et al. [28]. The small number of patients with
macroprolactinemia suggested that the increase of prolactin
is quite homogenous during pregnancy. Interestingly, re-
gardless of thyroid status, patients with macroprolactinemia
had the highest PRL levels (400 and 403 ng/mL) compared
with other patients. Our results were also similar to
Pascoe-Lira et al.’s study. They found that 3.8 % of the preg-
nant women had significant macroprolactinemia and total
PRL concentration was observed higher in those patients.
Another probable explanation for the discrepancy of pub-
lished results may be the detection method which is com-
monly used for macroprolactin measurement. Although
the gold standard method for detecting prolactin homogen-
eity or macroPRL is gel filtration chromatography, precipi-
tation with polyethylene glycol (PEG) is a widely used,
inexpensive, and easy screening test [7, 8, 29]. Therefore, if
we were using the latter method, results could have been
different. In general, however, this method is not widely
used, or available everywhere and recommended if bor-
derline measurement was obtained. In other words, gel
filtration chromatography would be necessary if 40-60 %
of prolactin recovery was detected after PEG precipitation
[30]. Almost all of our patients have shown >90 % persist-
ency from initial levels of monomeric prolactin after PEG
precipitation despite the clinical and laboratory differ-
ences. These data have supported the strong homogeneity
for PRL during pregnancy as well.
It has been shown that there is a strong association be-
tween thyroid and prolactin secretion physiologically. Many
critical and period-specific changes occur during pregnancy
in thyroid and prolactin metabolism. Due to the structural
similarity, elevated hCG may increase the synthesis of thy-
roid hormones and cause TSH suppression. Thus PRL re-
sponse to TRH may be blunted in hyperthyroid conditions.
In contrast, elevated TRH can increase levels of TSH and
PRL in patients with hypothyroidism [31, 32]. Autoimmune
thyroid disorders are common in women of reproductive
age and subclinical hypothyroidism related to chronic auto-
immune thyroiditis is the most common thyroid disorder.
If the classic reference range (0.4–4.0 μIU/L) of TSH is
used in the first trimester of pregnancy, subclinical cases of
hypothyroidism may be missed. Gestational transient thyro-
toxicosis (GTT) or hCG-mediated transient TSH suppres-
sion and Graves Disease (GD) are the most common types
of hyperthyroid disease in pregnant women. GTT is gener-
ally asymptomatic with mild biochemical hyperthyroidism
and may be exacerbated by hyperemesis, while GD is a real
thyrotoxic disease and mostly requires anti-thyroid treat-
ment. Both hypo and hyperthyroidism were reported to be
associated with poor pregnancy outcome. These outcomes
include spontaneous abortions, preterm birth, intrauterine
growth restriction, stillbirth, preeclampsia, heart failure,
and neurodevelopment deficits in the children [10–12].
In the present study, due to the complex relationship
between thyroid and prolactin metabolism, we tried to
examine patients by dividing them into three groups in
terms of thyroid status. The second aim of our study
was to evaluate prolactin homogeneity in different thy-
roid disorders during pregnancy. To the best of our
knowledge, the present study is the first study which in-
vestigated this relationship. Contrary to our expecta-
tions, macroprolactin levels did not increase during
pregnancy and there were only two patients with macro-
prolactinemia. All of the remaining patients showed
homogeneity in terms of prolactin size. We preferred to
use percentage of monoPRL recovery for the other pa-
tients to define homogeneity instead of macroprolactine-
mia for two reasons. Firstly because of the insufficient
number of patients with macroprolactinemia and the
secondly due to the fact that the definition of macropro-
lactinemia is already based on percentage of recovered
prolactin after PEG precipitation. Nevertheless, there
was a small amount of data that can be considered sig-
nificant. These findings were as follows, a slightly signifi-
cant positive correlation between TSH and PRL, and a
negative correlation between FT4 and PRL. Although
there is a known close relationship between thyroid and
prolactin metabolism, it was not so clear in the present
study. However, the number of marked hypothyroid and
hyperthyroid patients was inconsiderable in our study
and most of our patients were euthyroid. This can ex-
plain why we found serum prolactin levels similar and
not enough to confirm our hypothesis.
The other potential issue is the relationship of prolac-
tin with autoimmune processes. It was shown that pro-
lactin has the potential to stimulate the immune system
and can also be produced in extra pituitary sites [33, 34]. A
large number of autoantibodies are increased in pa-
tients with hyperprolactinemia without overt clinical
autoimmune disease. These antibodies include antipi-
tuitary, antithyroid peroxidase, antithyroglobulin, anti
gastric parietal cells, antimicrosomal, and anticardioli-
pin antibodies [35–38]. In addition, there is an intri-
guing relationship between macroprolactin and some
collagen tissue disorders such as SLE. It is proposed
that there is a correlation between disease activity and
macroprolactinemia [39, 40]. Initially we investigated
this relationship in different thyroid hormone status.
We could not find any relationship between thyroid
antibodies with either PRL or monoPRL %. Regardless
of thyroid status, according to the presence of TPOAb
alone, the negative tendency continued. It is well
known that antibodies may be high in healthy individ-
uals without apparent thyroid disease [41, 42]. Pres-
ence of high number of patients with positive thyroid
antibody, 81(58 %) in all groups, can be a reason for
statistical uncertainty.
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Conclusions
In conclusion; there were no significant contributions
of macroprolactin to prolactin levels during pregnancy.
The levels of prolactin showed strong homogeneity and
no correlation were found with thyroid dysfunction and
thyroid autoimmunity at that time. This uncertainty
persisted when correlation analyses was done with
monoPRL % instead of macroPRL. Ultimately, we could
not find any relationship between thyroid hormones
and antibodies with prolactin types in terms of molecu-
lar size.
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